Akebia Therapeutics Inc AKBA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-03-20 |
| Shares Out. | 268,260,000 |
| Website | akebia.com/ ↗ |
| Phone | 13026587581 |
| Employees | 194 |
| Revenue | $53.5M |
| Gross Profit | $41.3M |
| Net Income | -$9.1M |
| Free Cash Flow | $60.0M |
| Total Assets | $362.5M |
| Total Liabilities | $335.1M |
| Equity | $27.4M |
About Akebia Therapeutics Inc
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Akebia Therapeutics Inc is a publicly traded company under the ticker symbol AKBA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)